DiaMedica Therapeutics Inc. (DMAC)
- Previous Close
3.1800 - Open
3.1000 - Bid 3.1200 x 100
- Ask 3.2200 x 100
- Day's Range
3.0050 - 3.2300 - 52 Week Range
1.6700 - 4.7500 - Volume
18,055 - Avg. Volume
42,208 - Market Cap (intraday)
121.105M - Beta (5Y Monthly) 1.75
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6000 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
www.diamedica.comRecent News: DMAC
Performance Overview: DMAC
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DMAC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DMAC
Valuation Measures
Market Cap
121.10M
Enterprise Value
74.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.02%
Return on Equity (ttm)
-46.77%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-19.38M
Diluted EPS (ttm)
-0.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
52.9M
Total Debt/Equity (mrq)
0.78%
Levered Free Cash Flow (ttm)
-11.45M
Research Analysis: DMAC
Company Insights: DMAC
DMAC does not have Company Insights